urinary%20tract%20infection%20-%20complicated
URINARY TRACT INFECTION - COMPLICATED
Urinary tract infection (UTI) is complicated if the UTI is associated with factors that increases colonization and decreases therapy efficacy. Factors may include one or all of the following: Structural or functional abnormalities of the genitourinary tract; presence of an underlying disease that interferes with host defense mechanisms or the patient being immunocompromised; and being infected by a multi-drug resistant bacteria.
Principles of therapy includes effective antimicrobial antimicrobial therapy, optimal management of the underlying abnormalities or other diseases & adequate life-supporting measures.

Urinary%20tract%20infection%20-%20complicated Management

Indications For Hospital Admission

  • The decision to hospitalize the patient will depend on the severity of the illness
Consider hospitalization if any of the following exist:
  • Patient w/ complicated urinary tract infection & unable to maintain oral hydration or take oral medications
  • Concerns regarding patient adherence to treatment
  • Uncertainty of diagnosis
  • Severe illness w/ high fever & severe pain
  • Marked debility & signs of sepsis
Outpatient
  • Patients who do not meet the above categories may be considered for treatment on an outpatient basis

Follow Up

  • Perform urine analysis to ensure that causative agent has been eradicated
  • A urine culture obtained 1-2 weeks after completing therapy & thereafter as clinically indicated may also be done
  • Further genitourinary investigation should be made in cases of:
    • Delayed or incomplete response to appropriate antimicrobial therapy
    • Early recurrence of infection after therapy
  • Further follow-up to identify & correct anatomical, functional or metabolic abnormalities is indicated
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, Yesterday

Patients with coronavirus disease 2019 (COVID-19) who have haematologic malignancies have a 28 percent mortality rate, according to data collected from 250 patients by the ASH Research Collaborative COVID-19 presented at the 62nd American Society of Hematology Annual Meeting and Exposition (ASH 2020).

Roshini Claire Anthony, 01 Dec 2020

An evidence-based, multifaceted intervention aimed at reducing haemodialysis catheter-related bloodstream infections (HD-CRBSIs) failed to improve this outcome, results of the REDUCCTION* trial showed.

Pearl Toh, 5 days ago
While it is well known that COVID-19 illness is associated with coagulopathy, the optimal anticoagulation strategy remains elusive, and two studies presented at the ASH 2020 Congress further add to the growing debate on the appropriate anticoagulant dose for hospitalized patients with COVID-19.
Tristan Manalac, 2 days ago
People are more likely to follow social distancing measures for the novel coronavirus disease (COVID-19) pandemic when they thought that their friends and family did the same, too, according to a new study.